Skip to main content
SpringerLink
Log in

Oncostatin M and leukemia inhibitory factor increase hepcidin expression in hepatoma cell lines

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Overproduction of hepcidin by interleukin-6 (IL-6) is considered to be the main factor responsible for the development of anemia in inflammatory conditions. Since oncostatin M (OSM), a member of the IL-6 family, plays an important role in immune and inflammatory responses, we assessed the effect of OSM on hepcidin expression, as well as that of leukemia inhibitory factor (LIF), another member of the IL-6 family. We found that hepcidin expression was markedly induced by OSM and LIF in a time- and dose-dependent manner in hepatoma cell lines, and this expression was induced independent of IL-6/IL-6 receptor signaling. Luciferase assay revealed that OSM and LIF stimulated a −1.3-kb hepcidin promoter. This effect was markedly reduced when the signal transducer and activator of transcription (STAT) site of the promoter was mutated, and was almost completely abolished in the presence of AG-490, a Janus kinase (JAK) inhibitor. Hence, the JAK/STAT pathway plays a major role in OSM- and LIF-induced activation of the hepcidin promoter. In conclusion, we demonstrated that OSM and LIF can induce hepcidin expression mainly through the JAK/STAT pathways. Further studies are warranted to evaluate the clinical significance of OSM and LIF in the development of anemia in various inflammatory diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480:147–50.

    Article  CAS  PubMed  Google Scholar 

  2. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–10.

    Article  CAS  PubMed  Google Scholar 

  3. Andrews NC. Forging a field: the golden age of iron biology. Blood. 2008;112:219–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. Int J Hematol. 2008;88:7–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Sow FB, Florence WC, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP. Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis. J Leukoc Biol. 2007;82:934–45.

    Article  CAS  PubMed  Google Scholar 

  6. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–3.

    Article  CAS  PubMed  Google Scholar 

  7. Ganz T. Hepcidin: a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol. 2005;18:171–82.

    Article  CAS  PubMed  Google Scholar 

  8. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276:7811–9.

    Article  CAS  PubMed  Google Scholar 

  9. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron-regulatory hormone hepcidin. J Clin Invest. 2004;113:1271–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Beutler E. Iron storage disease: facts, fiction and progress. Blood Cells Mol Dis. 2007;39:140–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Anderson GJ, Powell LW. HFE and non-HFE hemochromatosis. Int J Hematol. 2002;76:203–7.

    Article  PubMed  Google Scholar 

  12. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA. 2005;102:1906–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Inamura J, Ikuta K, Jimbo J, Shindo M, Sato K, Torimoto Y, et al. Upregulation of hepcidin by interleukin-1 beta in human hepatoma cell lines. Hepatol Res. 2005;33:198–205.

    Article  CAS  PubMed  Google Scholar 

  14. Collins HL. Withholding iron as a cellular defence mechanism: friend or foe? Eur J Immunol. 2008;38:1803–6.

    Article  CAS  PubMed  Google Scholar 

  15. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461–3.

    Article  CAS  PubMed  Google Scholar 

  16. Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman’s disease. Haematologica. 2007;92:857–8.

    Article  CAS  PubMed  Google Scholar 

  17. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Malik N, Kallestad JC, Gunderson NL, Austin SD, Neubauer MG, Ochs V, et al. Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. Mol Cell Biol. 1989;9:2847–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Linsley PS, Kallestad J, Ochs V, Neubauer M. Cleavage of a hydrophilic C-terminal domain increases growth-inhibitory activity of oncostatin M. Mol Cell Biol. 1990;10:1882–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Grenier A, Dehoux M, Boutten A, Arce-Vicioso M, Durand G, Gougerot-Pocidalo MA, et al. Oncostatin M production and regulation by human polymorphonuclear neutrophils. Blood. 1999;93:1413–21.

    CAS  PubMed  Google Scholar 

  21. Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol. 1987;139:2977–83.

    CAS  PubMed  Google Scholar 

  22. Znoyko I, Sohara N, Spicer SS, Trojanowska M, Reuben A. Expression of oncostatin M and its receptors in normal and cirrhotic human liver. J Hepatol. 2005;43:893–900.

    Article  CAS  PubMed  Google Scholar 

  23. Suda T, Chida K, Todate A, Ide K, Asada K, Nakamura Y, et al. Oncostatin M production by human dendritic cells in response to bacterial products. Cytokine. 2002;17:335–40.

    Article  CAS  PubMed  Google Scholar 

  24. Richards CD, Brown TJ, Shoyab M, Baumann H, Gauldie J. Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. J Immunol. 1992;148:1731–6.

    CAS  PubMed  Google Scholar 

  25. Baumann H, Gauldie J. The acute phase response. Immunol Today. 1994;15:74–80.

    Article  CAS  PubMed  Google Scholar 

  26. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol. 2003;149:39–52.

    Article  CAS  PubMed  Google Scholar 

  27. Nakamura K, Nonaka H, Saito H, Tanaka M, Miyajima A. Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology. 2004;39:635–44.

    Article  PubMed  Google Scholar 

  28. Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom. 2007;21:4033–8.

    Article  CAS  PubMed  Google Scholar 

  29. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108:3204–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005;106:1864–6.

    Article  CAS  PubMed  Google Scholar 

  31. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006;108:1381–7.

    Article  CAS  PubMed  Google Scholar 

  32. Waterston A, Bower M. Fifty years of multicentric Castleman’s disease. Acta Oncol. 2004;43:698–704.

    Article  PubMed  Google Scholar 

  33. Lee P, Peng H, Gelbart T, Beutler E. The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci USA. 2004;101:9263–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Urbanska-Rys H, Wiersbowska A, Stepien H, Robak T. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma. Eur Cytokine Netw. 2000;11:443–51.

    CAS  PubMed  Google Scholar 

  35. Koskela K, Pelliniemi TT, Rajamaki A, Pulkki K, Remes K. Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis. Eur J Haematol. 2000;65:52–6.

    Article  CAS  PubMed  Google Scholar 

  36. Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, Roodman GD, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14:3262–7.

    Article  CAS  PubMed  Google Scholar 

  37. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112:4292–7.

    Article  CAS  PubMed  Google Scholar 

  38. Gearing DP, Gough NM, King JA, Hilton DJ, Nicola NA, Simpson RJ, et al. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J. 1987;6:3995–4002.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Gough NM. Molecular genetics of leukemia inhibitory factor (LIF) and its receptor. Growth Factors. 1992;7:175–9.

    Article  CAS  PubMed  Google Scholar 

  40. Brown MA, Metcalf D, Gough NM. Leukaemia inhibitory factor and interleukin 6 are expressed at very low levels in the normal adult mouse and are induced by inflammation. Cytokine. 1994;6:300–9.

    Article  CAS  PubMed  Google Scholar 

  41. Gearing DP. The leukemia inhibitory factor and its receptor. Adv Immunol. 1993;53:31–58.

    Article  CAS  PubMed  Google Scholar 

  42. Lorgeot V, Praloran V, Turlure P, Denizot Y. Concentrations of serum leukemia inhibitory factor (LIF) in patients with hematologic malignancies. Leukemia. 1997;11:311–2.

    Article  CAS  PubMed  Google Scholar 

  43. Koliaraki V, Marinou M, Vassilakopoulos TP, Vavourakis E, Tsochatzis E, Pangalis GA, et al. A novel immunological assay for hepcidin quantification in human serum. PLoS One. 2009;4:e4581.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109:353–8.

    Article  PubMed  Google Scholar 

  45. Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology. 2007;132:294–300.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. Hideyuki Tsuchida (Division of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan) for measuring the hepcidin-25 levels in the cell culture supernatant. This work was supported in part by a grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan; a grant from Takeda Science Foundation; and a grant for Project Research from the High-Technology Center of Kanazawa Medical University (H2007-2).

Conflict of interest statement

N.T. declares that he is also the President of Medical Care Proteomics Biotechnology Co. Ltd. (Ishikawa-ken, Japan), a start-up company, the stocks of which are not publicly traded. Other authors declare that they have no conflicts of interest relevant to this paper.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan

    Junya Kanda, Tatsuki Uchiyama, Takashi Uchiyama & Hiroshi Kawabata

  2. Proteomics Research Unit, Division of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan

    Naohisa Tomosugi & Masato Higuchi

  3. Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan

    Takashi Uchiyama

Authors
  1. Junya Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tatsuki Uchiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naohisa Tomosugi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masato Higuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takashi Uchiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Kawabata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Kawabata.

About this article

Cite this article

Kanda, J., Uchiyama, T., Tomosugi, N. et al. Oncostatin M and leukemia inhibitory factor increase hepcidin expression in hepatoma cell lines. Int J Hematol 90, 545–552 (2009). https://doi.org/10.1007/s12185-009-0443-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-009-0443-x

Keywords

Search

Navigation